Ozanimod efficacy in relapsing multiple sclerosis supported by open-label long-term extension of two phase 3 trials

Authors
Category Primary study
JournalNeurology
Year 2019
This article has no abstract
Epistemonikos ID: 4a4523fc54cb7a5a0310617d2faba06f89ff43b3
First added on: Feb 11, 2025